Stryker Corporation has announced the acquisition of Amplitude Vascular Systems, a company specialising in innovative peripheral vascular technologies. The deal is aimed at strengthening Stryker’s portfolio in the fast-growing peripheral vascular market, particularly in areas such as atherectomy, drug-coated balloons, and minimally invasive treatments for peripheral artery disease (PAD).
Glimpse:
Amplitude Vascular Systems brings advanced, next generation solutions for treating peripheral vascular conditions. The acquisition will allow Stryker to expand its offerings in endovascular interventions, enhance its competitive position, and better serve patients suffering from peripheral artery disease and related vascular complications.
Stryker, a global leader in medical technology, has agreed to acquire Amplitude Vascular Systems to significantly enhance its capabilities in the peripheral vascular segment. This strategic move is expected to broaden Stryker’s product lineup with cutting edge technologies designed for the treatment of peripheral artery disease and other vascular disorders.
Amplitude Vascular Systems is known for developing specialised devices used in minimally invasive endovascular procedures, including advanced atherectomy systems and drug delivery technologies. The acquisition will integrate these innovations into Stryker’s existing vascular and endovascular portfolio, enabling the company to offer more comprehensive solutions to interventional cardiologists, vascular surgeons, and radiologists.
Peripheral artery disease affects millions of people worldwide and is a growing area of focus in vascular care. With this acquisition, Stryker aims to strengthen its position in this high potential market and accelerate the development and adoption of next generation therapies.
The transaction is subject to customary closing conditions and is expected to be completed in the coming months.
“This acquisition aligns with our strategy to expand in high growth vascular markets and deliver best in class solutions that improve patient outcomes.”
By
HB Team
